VMD Form 4: Michael Moore reports sale of 50,090 shares; holds 1.72M indirectly

Rhea-AI Filing Summary

Michael Moore, President of Viemed Healthcare (VMD), reported an insider sale. The Form 4 shows a sale of 50,090 common shares on 08/12/2025 at a price of $7.33 per share. After the transaction Moore directly owns 126,343 shares and indirectly beneficially owns 1,722,614 shares through Moore Faster LLC. The filing discloses the sale but provides no context about volume relative to total outstanding shares.

Insights

Corporate Governance Expert

TL;DR: Routine insider sale by the company president; significant indirect holdings remain.

The filing documents a straightforward sale of 50,090 shares by President Michael Moore at $7.33 each. While the direct stake falls to 126,343 shares, the report shows a substantial indirect holding of 1,722,614 shares via Moore Faster LLC, which indicates ongoing significant economic exposure despite the sale. The filing does not state whether the sale was part of a pre-arranged plan, nor does it provide context versus total shares outstanding, limiting assessment of materiality.

Securities Analyst

TL;DR: Transaction is a disclosed insider sale; lacking broader context, it reads as informational rather than material.

The Form 4 reports an open-market sale (transaction code "S") of 50,090 shares at $7.33 on 08/12/2025. The reporting person retains both direct and large indirect positions, which may mitigate concerns about alignment. Without company share count or additional insider activity, this single sale does not alone indicate a change in corporate outlook.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moore Michael

(Last) (First) (Middle)

625 E. KALISTE SALOOM RD.

(Street)

LAFAYETTE LA 70508

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/12/2025		S		50,090	D	$7.33	126,343	D
Common Shares								1,722,614	I	by Moore Faster LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Jesse Bergeron, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Viemed (VMD)?

Michael Moore, identified as the company's President, is the reporting person on the Form 4.

What transaction is reported on the VMD Form 4?

Sale of 50,090 common shares on 08/12/2025 at a price of $7.33 per share (transaction code "S").

How many Viemed shares does Michael Moore own after the sale?

The filing shows 126,343 shares owned directly and 1,722,614 shares owned indirectly through Moore Faster LLC.

Was the sale reported under a 10b5-1 trading plan on the Form 4?

The Form 4 does not indicate that the transaction was made pursuant to a Rule 10b5-1 plan; no such designation is specified in the filing.

Who signed the Form 4 filing as the reporting person's representative?

The signature block shows Jesse Bergeron, Attorney-in-Fact as the signatory for the reporting person.